je.st
news
Home
› Pfizer And Synthon Enter Into U.S. Commercialization Agreement For Potential Generic Treatment Of Multiple Sclerosis
Pfizer And Synthon Enter Into U.S. Commercialization Agreement For Potential Generic Treatment Of Multiple Sclerosis
2015-08-05 07:09:59| drugdiscoveryonline Home Page
Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, recently announced they have entered into an agreement whereby Pfizer has acquired the exclusive commercialization rights in the United States to glatiramer acetate, a potential generic version of the originator medicine Copaxone for the treatment of relapsing remitting multiple sclerosis (RRMS)
Tags: of
enter
agreement
multiple
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||